Please find enclosed notice of 8th Annual General Meeting of the Company to be held on 27th December, 2025. Please take the same on record.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astonea Labs Limited (BSE Scrip: 544409) has issued the notice for its 8th AGM scheduled for Saturday, 27th December 2025 at 11:00 AM in physical mode at Mercure Hotel, Chandigarh. Ordinary business includes adoption of audited FY25 financial statements and noting the retirement of Mr. Pardeep Singh (who is not seeking re-appointment), with Mr. Vikrant proposed in his place. Special business includes several significant items: (1) approval to set up foreign subsidiaries and joint ventures, (2) acquiring a 33.33% equity stake in Damaira Pharmaceuticals Private Limited, (3) modification or variation in the utilisation of IPO proceeds (the company listed via IPO in June 2025), (4) voluntary adoption of Ind AS from FY 2026-27, and (5) regularisation of Mr. Pardeep Dalal, Mr. Arun Kumar Tripathi, and the change in designation of Mr. Vikrant from Non-Executive Non-Independent Director to Executive Director. E-voting cut-off date is 19th December 2025, with remote e-voting window from 24th to 26th December 2025.
This AGM carries multiple strategic resolutions beyond routine approvals. Shareholders should pay close attention to the proposed acquisition of Damaira Pharmaceuticals, the reallocation of recently raised IPO funds, the push into foreign subsidiaries/JVs, and the conversion of Mr. Vikrant to Executive Director - all of which could reshape the company's growth direction, capital allocation, and future financial reporting. The meeting outcome may influence near-term stock sentiment given the materiality of the acquisition and IPO-proceeds variance items.